Simonsen C C, McGrogan M
Sierra BioResource, Inc., Gilroy, CA 95020.
Biologicals. 1994 Jun;22(2):85-94. doi: 10.1006/biol.1994.1014.
The emergence of a wide variety of biological expression systems for the large-scale production of therapeutic proteins has shifted the focus from vectors to host organisms. Although expression systems now span bacteria, fungi, plants, insects, and mammalian cells, the vast majority of recombinant-derived biopharmaceuticals at the present time have been produced in Escherichia coli and in mammalian cells. This promises to change as the economic benefits of the newer systems permit the development of a new generation of proteins heretofore considered unfeasible for commercial development. Despite the impressive results which have been observed for many of the newer systems, there are many commercial considerations which suggest that E. coli and CHO cell expression systems may continue to dominate the manufacture of biopharmaceuticals for a long time to come.
用于大规模生产治疗性蛋白质的多种生物表达系统的出现，已将关注点从载体转移到宿主生物体。尽管目前表达系统涵盖细菌、真菌、植物、昆虫和哺乳动物细胞，但目前绝大多数重组衍生的生物制药产品是在大肠杆菌和哺乳动物细胞中生产的。随着新系统的经济效益允许开发新一代迄今被认为商业开发不可行的蛋白质，这种情况有望改变。尽管许多新系统已取得令人瞩目的成果，但许多商业考量表明，大肠杆菌和CHO细胞表达系统可能在未来很长一段时间内继续主导生物制药的生产。
